OBJECTIVES: Prognostic risk factors influencing survival in @entity1 with @entity43 ( @entity43 ) include @entity5 stage, grade, histologic subtype, debulking, and @entity902 status. Little is known about the impact of hormonal milieu and reproductive factors before @entity5 diagnosis on clinical outcome. We sought to evaluate whether @entity5708 (OC) use carries any prognostic significance on overall survival (OS) in @entity1 with @entity43 . METHODS: Newly diagnosed @entity1 with @entity43 , fallopian tube, and primary peritoneal @entity5 between 1982 and 1998 were prospectively evaluated with a comprehensive epidemiologic questionnaire. A retrospective chart review was performed to abstract clinicopathologic data, including OS. A Kaplan-Meier analysis was performed to compare survival across various exposures. A Cox regression model was used to compute adjusted hazards ratios (aHRs) and 95% confidence intervals (CIs). RESULTS: We identified 387 newly diagnosed @entity5 with evaluable information in this cohort. @entity204 was observed in @entity1 who reported prior use of OC ( @entity5874 , 0.79; 95% CI, 0.58-1.09), previous pregnancy ( @entity5874 , 0.77; 95% CI, 0.57-1.04), or a live birth ( @entity5874 , 0.81; 95% CI, 0.60-1.08) after adjusting for age at diagnosis, stage, and histologic subtype. Oral contraceptive use was associated with a crude reduced risk of @entity204 (HR, 0.55; 95% CI, 0.42-0.72), with reported median OS of 81 months in OC users versus 46 months in nonusers. @entity1 who reported a single live birth experienced the largest potential survival advantage ( @entity5874 , 0.61; 95% CI, 0.39-0.94). Oral contraceptive use and prior pregnancy were associated with improved survival across all strata. CONCLUSIONS: Oral contraceptive use may have lasting effects on @entity43 characteristics conferring favorable prognosis. Putative mechanisms that affect @entity5 biology include complex interactions between ovarian cells, host immune cells, and hormonal microenvironment during carcinogenesis. Future efforts should be directed to determine the role of reproductive factors in antitumor immunity.

Oral Contraceptive Use and Reproductive Characteristics Affect Survival in @entity1 With XXXX : A Cohort Study.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['EOC', 'epithelial ovarian tumor', 'epithelial ovarian cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer'] @entity5874 :: ('196', 'Gene') :: ['aHR'] @entity204 :: ('MESH:D003643', 'Disease') :: ['Decreased risk of death', 'death'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity5708 :: ('D003276', 'Chemical') :: ['oral contraceptive']
@entity43 :: (MESH:D010051,Disease) :: ['Epithelial Ovarian Cancer']
